|
MED6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.31594776479005E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.88179999255556E-09 |
| Normal-vs-Stage2 |
1.28909999996818E-06 |
| Normal-vs-Stage3 |
6.46949160909571E-12 |
| Normal-vs-Stage4 |
2.02819983030622E-11 |
| Stage1-vs-Stage2 |
8.748400E-01 |
| Stage1-vs-Stage3 |
8.906000E-02 |
| Stage1-vs-Stage4 |
2.098100E-02 |
| Stage2-vs-Stage3 |
2.886400E-01 |
| Stage2-vs-Stage4 |
1.362230E-01 |
| Stage3-vs-Stage4 |
5.326800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.90479965134216E-10 |
| Normal-vs-AfricanAmerican |
1.97318999999307E-05 |
| Normal-vs-Asian |
1.12850000011377E-07 |
| Caucasian-vs-AfricanAmerican |
9.778400E-01 |
| Caucasian-vs-Asian |
8.584800E-01 |
| AfricanAmerican-vs-Asian |
9.302000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.27689003604337E-13 |
| Normal-vs-Female |
2.71630051784655E-10 |
| Male-vs-Female |
2.072000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.42620035173502E-10 |
| Normal-vs-Age(41-60Yrs) |
4.04959999977805E-08 |
| Normal-vs-Age(61-80Yrs) |
1.73061565078569E-12 |
| Normal-vs-Age(81-100Yrs) |
1.142030E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.868000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.683600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.904600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.417980E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.295000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.420800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.805890E-02 |
| Classical-VS-Follicular |
1.730310E-02 |
| Classical-VS-Other |
2.955200E-01 |
| Classical-VS-Normal |
1.5596000046969E-09 |
| Tall-VS-Follicular |
6.176600E-01 |
| Tall-VS-Other |
9.134000E-01 |
| Tall-VS-Normal |
3.66569996579358E-09 |
| Follicular-VS-Other |
9.312400E-01 |
| Follicular-VS-Normal |
2.4377999618963E-09 |
| Other-VS-Normal |
2.302800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.99259497790649E-11 |
| Normal-vs-N1 |
1.8572998694566E-10 |
| N0-vs-N1 |
1.803180E-01 |
|
|
